Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the company's pneumococcal conjugate vaccine, Prevenar ...
Maidenhead, England (ots/PRNewswire) - - 26 Men and Women With RA From Across Europe Honoured as They Share Their Inspirational Stories Actress, artist and activist Jane Seymour will host the first My Day for RA European event in Barcelona, Spain this evening to recognise the daily challenges, hopes and ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announces findings from a placebo-controlled Phase 3 study of bazedoxifene 20 mg extended to five years, which indicated a significant reduction versus placebo in new vertebral fractures in postmenopausal women with osteoporosis. These and other data were ...
Maidenhead, England (ots/PRNewswire) - - Study Published in Rheumatology Underscores the Need for Early and Aggressive Treatment to Maintain Work Productivity Patients receiving Enbrel(R) (etanercept) in combination with methotrexate for early RA are more likely to continue working, according to the COMET study published today in Rheumatology. One year ...
Maidenhead, England (ots/PRNewswire) - Wyeth Europa Ltd., a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved the mTOR (mammalian target of rapamycin) inhibitor TORISEL(R) (temsirolimus) for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma ...
Vienna (ots/PRNewswire) - Elan Corporation, plc (NYSE: ELN) and Wyeth (NYSE: WYE) presented information this week at the Alzheimer Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) from seven posters and one podium presentation about the growing burden of care and costs associated ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Chile Grants First Approval of Prevenar 13 for the Prevention of Pneumococcal Disease in Infants and Children- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the Chilean Ministry of Health, MINSAL (Ministerio de Salud), has become the first government agency to approve Prevenar 13* Valent, (Pneumococcal Conjugate Vaccine 13 Valent ...
Maidenhead, England (ots/PRNewswire) - - Prevenar Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Worldwide Israel has initiated a national immunisation programme (NIP) against pneumococcal disease with Wyeth Pharmaceuticals' vaccine Prevenar(tm) ...
Maidenhead, England (ots/PRNewswire) - - Two-year Data From COMET Study in Early Active Moderate-to-Severe Rheumatoid Arthritis Indicated Sustained Halt of Progressive Joint Damage - New Analyses From ASCEND Study in Ankylosing Spondylitis Indicated Improvement in Patients With and Without Peripheral ...
Collegeville, Pennsylvania (ots/PRNewswire) - New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE: WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent [Adsorbed]), has the potential to provide coverage against the 13 most ...
Maidenhead, England (ots/PRNewswire) - - CHMP Recommends Approval of a Continuous Dosing Regimen Option for Enbrel In Plaque Psoriasis, and a New Pre-Filled Pen Delivery Device Today, Wyeth received positive recommendations from the European Committee for Medicinal Products for Human Use (CHMP) for two ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced preliminary data from two ongoing studies, one evaluating neratinib (HKI-272) in combination with trastuzumab (Herceptin(R), Roche) in HER-2 positive (ErbB-2 positive) breast cancer, and ...
Collegeville, Pennsylvania (ots/PRNewswire) - -- Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) granted priority review to the company's Biologic License Application ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has granted marketing authorization for CONBRIZA(TM) (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Wyeth and Advocacy Community Mark Continued Commitment to Patient Care on World Hemophilia Day In honor of the twentieth Anniversary of World Hemophilia Day, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), together with the World Federation of Hemophilia (WFH), announce the addition of five new ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Candidate vaccine designed to protect against the 13 most prevalent serotypes associated with pneumococcal disease - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a Biologic License Application (BLA) to the ...
Amsterdam (ots/PRNewswire) - - Psoriasis Patients from Around the World Come together to Bare Their Skin and Share Their Stories for New Pan-European Educational Programme AMSTERDAM, March 26 /PRNewswire/ -- Psoriasis: The Naked Truth, a new pan-European educational programme to expose the physical and ...
Maidenhead, England (ots/PRNewswire) - - Prevenar Helps Protect Children Against the Leading Vaccine-Preventable Cause of Death in Children Younger than Five Years of Age Worldwide Wyeth today announced that Prevenar(TM) (Pneumococcal saccharide conjugated vaccine, Adsorbed) has been added to Saudi ...
Maidenhead, England (ots/PRNewswire) - - Improvements in Purification Process Represent Important Advance in the Treatment of Haemophilia A Wyeth announced today it has received a positive decision from the European Commission for a variation of the marketing authorisation for ReFacto moroctocog alfa ...
Maidenhead, England (ots/PRNewswire) - - Prevenar Vaccine Helps Protect Against Leading Vaccine-Preventable Cause of Death in Young Children Worldwide Wyeth announced today that its 7-valent pneumococcal conjugate vaccine, Prevenar(TM) (Pneumococcal saccharide conjugated vaccine, Adsorbed), has been registered by the Russian Ministry of Health and Social ...
Collegeville, Pennsylvania (ots/PRNewswire) - The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), today adopted a positive opinion recommending to grant a marketing authorization for CONBRIZA(TM) (bazedoxifene) for the treatment ...
Maidenhead, England (ots/PRNewswire) - - Prevenar Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Worldwide Turkey has initiated a national immunization programme (NIP) against pneumococcal disease with Wyeth's Prevenar(TM) (Pneumococcal saccharide ...
Maidenhead, England (ots/PRNewswire) - - New Data Add to the Body of Evidence That Show That Enbrel (Etanercept) Clears Skin and Can Sustain This Efficacy Over Time New data presented today at the 'Gene to Clinic' meeting taking place at the Royal College of Physicians in London, England, reinforce ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Approval sought for investigational vaccine for protection against the 13 most prevalent serotypes associated with serious pneumococcal disease Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has submitted a marketing ...
Maidenhead, England, November 21 (ots/PRNewswire) - - Not for UK Journalists The European Committee for Medicinal Products for Human Use (CHMP) today announced its positive recommendation for the approval of Enbrel(R) (etanercept) as a treatment for children aged 8 years and over and adolescents with ...
Washington (ots/PRNewswire) - - Data presented at the joint annual meeting of ICAAC and IDSA - Results suggest candidate vaccine may be as effective as Prevnar for the seven shared serotypes, and provide expanded coverage for six additional serotypes - Wyeth on track to complete U.S. filing for ...
Maidenhead, England (ots/PRNewswire) - - Data From Another Study Supported the use of ENBREL for up to Five Years in Ankylosing Spondylitis Patients New safety and efficacy data for active ankylosing spondylitis (AS) patients treated with ENBREL(R) (etanercept) were presented at the American College of ...
Collegeville, Pennsylvania (ots/PRNewswire) - - Company Underscores Commitment to Availability in Worldwide Markets Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today provided an update on its global strategy for desvenlafaxine for the treatment of major depressive disorder (MDD) in adults. ...
Collegeville, Pennsylvania (ots/PRNewswire) - - 85,000 Expected to Enroll in Phase 4 Study Initiated Pre-Registration - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced the initiation of the Community Acquired Pneumonia Immunization Trial in Adults a major study in adults of an investigational 13-valent conjugate vaccine designed to help prevent pneumococcal pneumonia -- the leading cause ...
Maidenhead, England (ots/PRNewswire) - - Data Represents More than 800 Patient Years of Experience Wyeth today announced study results from last week's 15th Paediatric Rheumatology European Congress (PRES) in London which highlight the safety record of etanercept (ENBREL(R)) as a continuous therapy in ...